Table 1.
The clinical characteristics of patients according to periostin expression
| Variables | Periostin expression in epithelial cells of tumor tissue | Periostin expression level in epithelial cell-negative tumor tissue | ||||
|---|---|---|---|---|---|---|
| Negative (n=536) | Positive (n=139) | P-value | Low (n=371) | High (n=164) | P-value | |
| Age (years), n (%) | 0.098 | 0.155 | ||||
| <60 | 275 (53.9) | 61 (45.9) | 181 (51.7) | 93 (58.5) | ||
| ≥60 | 235 (46.2) | 72 (53.7) | 169 (48.3) | 66 (41.5) | ||
| Gender, n (%) | 0.018 | 0.288 | ||||
| Male | 358 (69.1) | 108 (79.4) | 251 (70.5) | 106 (65.8) | ||
| Female | 160 (30.9) | 28 (20.6) | 105 (29.5) | 55 (34.2) | ||
| Differentiation status, n (%) | <0.001 | 0.831 | ||||
| Well and moderate | 147 (31.1) | 62 (47.7) | 101 (30.7) | 45 (31.7) | ||
| Poor and undifferentiated | 325 (68.9) | 68 (52.3) | 228 (69.3) | 97 (68.3) | ||
| Lauren type, n (%) | <0.001 | 0.068 | ||||
| Intestinal type | 247 (46.6) | 91 (66.9) | 161 (43.9) | 85 (52.5) | ||
| Diffuse type | 283 (53.4) | 45 (33.1) | 206 (56.1) | 77 (47.5) | ||
| Serum CEA (ng/mL), n (%) | 0.538 | 0.305 | ||||
| <5 | 406 (82.5) | 101 (80.2) | 273 (81.5) | 133 (85.3) | ||
| ≥5 | 86 (17.5) | 25 (19.8) | 62 (18.5) | 23 (14.7) | ||
| Serum CA19-9 (U/mL), n (%) | 0.755 | 0.481 | ||||
| <37 | 394 (83.8) | 102 (85.0) | 263 (83.0) | 130 (85.5) | ||
| ≥37 | 76 (16.2) | 18 (15.0) | 54 (17.0) | 22 (14.5) | ||
| Serum CA72-4 (U/mL), n (%) | 0.934 | 0.782 | ||||
| <6.9 | 295 (78.2) | 70 (78.7) | 196 (77.8) | 98 (79.0) | ||
| ≥6.9 | 82 (21.8) | 19 (21.3) | 56 (22.2) | 26 (21.0) | ||
| Depth of invasion, n (%) | 0.006 | <0.001 | ||||
| T1+T2 | 176 (34.0) | 63 (46.7) | 103 (28.9) | 73 (45.3) | ||
| T3+T4 | 342 (66.0) | 72 (53.3) | 253 (71.1) | 88 (54.7) | ||
| Lymph node involvement, n (%) | <0.001 | 0.002 | ||||
| No | 185 (35.7) | 71 (52.2) | 111 (31.2) | 73 (45.3) | ||
| Yes | 333 (64.3) | 65 (47.8) | 245 (68.8) | 88 (54.7) | ||
| TNM stage, n (%) | 0.002 | <0.001 | ||||
| I+II | 238 (45.9) | 82 (60.7) | 145 (40.7) | 93 (57.8) | ||
| III+IV | 280 (54.1) | 53 (39.3) | 211 (59.3) | 68 (42.2) | ||
Abbreviations: CA19-9, carbohydrate antigen 19-9; CA72-4, carbohydrate antigen 72-4; CEA, carcinoembryonic antigen.